Australia - English - Department of Health (Therapeutic Goods Administration)

sonic equipment australia pty ltd - 34891 - stimulator, caloric, vestibular function - the air fx air irrigator dispenses cool or warm air to perform caloric tests for vestibular diagnosis. the aqua stim caloric irrigator is used for stimulation the motion sensors in the ear using warm or cool water pumped into the external ear canal. this standard clinical test is used to determine if the motion sensors are working properly in patients with dizziness or balance problems

Australia - English - Department of Health (Therapeutic Goods Administration)

natus medical pty ltd - 34891 - stimulator, caloric, vestibular function - to stimulate and measure nastagmagraphic potentials to test balance.

Australia - English - Department of Health (Therapeutic Goods Administration)

interacoustics pty ltd - 34891 - stimulator, caloric, vestibular function - a stimulator that applies heat stimuli in the form of a stream of air or water into the ear canal. vestibular function stimulators consist of an irrigation system that include a pump, valves, heaters, regulators to control the rate of flow and temperature of the medium. the stimulation of the semicircular canal produces involuntary eye movements which are measured using a nystagmograph. it is used for vestibular function testing for assessing the patient's balance system.

Australia - English - Department of Health (Therapeutic Goods Administration)

sonic equipment australia pty ltd - 34891 - stimulator, caloric, vestibular function - intended for the testing of vestibular function. this range of vestibular testers covers both water and air testing.

Australia - English - Department of Health (Therapeutic Goods Administration)

sonic equipment australia pty ltd - 34891 - stimulator, caloric, vestibular function - intended to dispense cool or warm air to perform caloric tests for vestibular diagnosis. this standard clinical test is used to determine if the motion sensors are working properly in patients with dizziness or balance problems

Bangladesh - English - DGDA (Directorate General of Drug Administration)

f-sons unani laboratories - qurs salajeet - tablet

European Union - English - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - orlistat - obesity - antiobesity preparations, excl. diet products - alli is indicated for weight loss in adults who are overweight (body mass index, bmi, ≥ 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet.

European Union - English - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - orlistat - obesity - antiobesity preparations, excl. diet products - xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (bmi) greater or equal to 30 kg/m2, or overweight patients (bmi > 28 kg/m2) with associated risk factors.treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - orlistat, quantity: 120 mg - capsule, hard - excipient ingredients: sodium lauryl sulfate; sodium starch glycollate type a; hydrophobic colloidal silica anhydrous; microcrystalline cellulose; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin - prolistat is indicated for the treatment of obese patients with a body mass index (bmi) ? 30, and overweight patients with a bmi ? 27 in the presence of other risk factors, in conjunction with a mildly hypocaloric diet.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - orlistat, quantity: 120 mg - capsule, hard - excipient ingredients: lecithin; gelatin; sodium lauryl sulfate; dimeticone 1510; indigo carmine; sodium starch glycollate; iron oxide black; titanium dioxide; microcrystalline cellulose; shellac; purified talc; povidone - xenical is indicated for the treatment of obese patients with a body mass index (bmi) >= 30, and overweight patients with a bmi >= 27 in the presence of other risk factors, in conjunction with a mildly hypocaloric diet.